Hui-Yu Chuang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Hui-Yu Chuang has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Alphonsus H. C. Ng
Institute for Systems Biology, Seattle, WA, USA
1 shared publication- Antoni Ribas
Department of Medicine, Division of Hematology and Oncology, University of California, Los Angeles, Los Angeles, USA
1 shared publication - Charles David Warden
Integrative Genomics Core, Department of Molecular and Cellular Biology, City of Hope, Duarte, California, United States
1 shared publication Chunmei Liu
Institute for Systems Biology, Seattle, WA, USA
1 shared publicationDaniel Chen
Institute for Systems Biology, Seattle, WA, USA
1 shared publication- David Baltimore
Dept of Surgical Research, Larner College of Medicine, University of Vermont
1 shared publication
Latest Publications
- Open Access
- 15 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Sequential transcriptional waves and NF-κB-driven chromatin remodeling direct drug-induced dedifferentiation in cancer
Drug-induced dedifferentiation towards drug-tolerant persister states is a common mechanism cancer cells exploit to escape therapies, hindering durable responses. How early epigenomic and transcriptomic programs coordinate to initiate these reversible transitions remains largely unexplored. Here we employ high-temporal-resolution multi-omics profiling, information-theoretic approaches, and dynamic system modeling to probe these processes in BRAF-mutant melanoma models and patient specimens. We uncover a hysteretic transition trajectory in response to oncogene inhibition and subsequent release, driven by two tightly coupled transcriptional waves that orchestrate genome-scale chromatin reconfiguration. Modeling of these waves suggests NF-κB/RelA-driven chromatin remodeling as the underlying mechanism of cell-state dedifferentiation, which we validate experimentally. We identify RelA-target genes epigenetically modulated to drive this process and define a quantitative epigenome gauge of melanoma cell-state plasticity that supports targeting epigenetic machineries to potentiate oncogene inhibition. Across additional cancer models, oxidative stress-mediated NF-κB/RelA activation emerges as a common driver of transitions into drug-tolerant persister states, revealing a central role for NF-κB axis in coupling oxidative stress to cancer progression.
- 15 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessSequential transcriptional waves and NF-κB-driven chromatin remodeling direct drug-induced dedifferentiation in cancer
Drug-induced dedifferentiation towards drug-tolerant persister states is a common mechanism cancer cells exploit to escape therapies, hindering durable responses. How early epigenomic and transcriptomic programs coordinate to initiate these reversible transitions remains largely unexplored. Here we employ high-temporal-resolution multi-omics profiling, information-theoretic approaches, and dynamic system modeling to probe these processes in BRAF-mutant melanoma models and patient specimens. We uncover a hysteretic transition trajectory in response to oncogene inhibition and subsequent release, driven by two tightly coupled transcriptional waves that orchestrate genome-scale chromatin reconfiguration. Modeling of these waves suggests NF-κB/RelA-driven chromatin remodeling as the underlying mechanism of cell-state dedifferentiation, which we validate experimentally. We identify RelA-target genes epigenetically modulated to drive this process and define a quantitative epigenome gauge of melanoma cell-state plasticity that supports targeting epigenetic machineries to potentiate oncogene inhibition. Across additional cancer models, oxidative stress-mediated NF-κB/RelA activation emerges as a common driver of transitions into drug-tolerant persister states, revealing a central role for NF-κB axis in coupling oxidative stress to cancer progression.